In the current investigation 365 primary breast cancer specimens were included and an overall HER2 status agreement close to 98% is reported when comparing test results obtained by HER2 CISH pharmDxTM Kit to results obtained by HER2 FISH pharmDxTM and PathVysion HER-2 FISH DNA Probe Kit. The gene discussed is ERBB2; the disease is breast carcinoma.